Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease
|
|
- Alicia Phillips
- 6 years ago
- Views:
Transcription
1 Clinical and Molecular Approach to Using Thyroid Needle Biopsy for Nodular Disease Robert L. Ferris, MD, PhD Department of Otolaryngology/Head and Neck Surgery and Yuri E. Nikiforov, MD, PhD Division of Molecular Anatomic Pathology University of Pittsburgh School of Medicine Objectives To provide an overview of molecular alterations in thyroid tumors To discuss specimen requirements for molecular testing in thyroid samples To discuss the diagnostic and prognostic utility of specific molecular markers in thyroid surgical resections and fine needle aspiration (FNA) samples
2 Trends in Incidence of Thyroid Cancer ( ) and Papillary Tumors by Size ( ) in the United States Thyroid Cancer Incidence and Mortality, Davies, L. et al. JAMA 2006;295: Risk of Cancer in a Thyroid nodule 3 5% in a woman age Age Sex Size Cystic Radiation as youth Standard for Evaluation Fine needle aspirate (FNA)
3 Benign Interpretation of FNA Malignant 1 Follicular/FLUS 2 Inadequate 2 1 ATA 2009 guidelines for central neck dissection are vague cytology may be the only information we have preoperatively 2 For certain cytologic diagnoses, lobectomy is a diagnostic procedure
4 Thyroid Nodules and FNA Cytology FNA cytology establishes definitive diagnosis in most cases 15-30% reported as indeterminate Category Risk of malignancy FLUS 5-10% Follicular neoplasm/lesion 20-30% Suspicious for malignancy 50-75% Baloch ZW et al. Diagn Cytopathol (2008) FNA cytology Positive for Malignancy 1-2% false positive Management of Patients with Thyroid Nodules Total Thyroidectomy I-131 Therapy Negative for Malignancy 1-3% false negative Indeterminate LUS or Follicular neoplasm Thyroid Lobectomy Completion Thyroidectomy I-131 Therapy
5 TSHR RTK Papillary carcinoma Follicular carcinoma β α γ RET/PTC 15% Adenylate cyclase camp PKA 15% 45% MAPK Pathway RAS BRAF MEK 45% PI3K AKT mtor PTEN PI3K/AKT Pathway ERK 30% PAX8/PPARγ Mutations in Papillary Carcinoma BRAF 45% N RET/PTC 15% ~75% Papillary CA RAS 15%
6 Mutations in Papillary Carcinoma BRAF 45% Tall cell and classical papillary CA Extrathyroidal extension Higher stage at presentation Higher rate of tumor recurrence Propensity for dedifferentiation N RET/PTC 15% RAS 15% Classic papillary CA Younger age at presentation Assoc. with radiation exposure Frequent l/node metastasis Lower stage at presentation Follicular variant of PTC More frequent encapsulation Less frequent l/node metastasis More frequent distant metastases Mutations in Follicular Carcinoma FA FC N 40% 30% FC ~70% Follicular CA
7 Mutations in Follicular Carcinoma N FA FC 40% 30% FC Larger tumor size Higher rate of distant metastasis Propensity for dedifferentiation Younger age of presentation Smaller tumor size Solid/nested growth pattern More frequent vascular invasion BRAF Mutations in Thyroid Nodules: Prevalence and Specificity Number of cases reported Benign Nodules BRAF V600E 1 (0.16%) Follicular Carcinoma Papillary Carcinoma PDC and AC % (30-83%) 21% (0-50%) Meta-analysis of literature
8 BRAF V600E Predicts Tumor Aggressiveness Multicenter study, 107 patients Single institution, 190 patients Xing et al. JCEM (2005) Xing, M. et al. J Clin Oncol; 27: Prevalence and Specificity of Mutant RAS Detection Goiter Follicular adenoma Follicular Carcinoma Papillary Carcinoma PDCA and AC Range 0-20% 20-45% 40-50% 0-20% 20-90% Average 5% 34% 45% 15% 30% Meta-analysis of literature
9 Prevalence and Specificity of PAX8/PPAR Detection Goiter Follicular adenoma Follicular Carcinoma Papillary Carcinoma PDCA and AC Range % 20-70% 0-5% 0 Average 0 7% 30% 1% 0 Meta-analysis of literature Molecular Diagnostics in Thyroid FNA Samples
10 Detection of Mutations in Thyroid FNA Samples Individual mutations/retrospective studies: RAS Sciacchitano S et al. Diagn Mol Pathol (1994) RET/PTC - Cheung C et al. JCEM (2001), Salvatore G et al. JCEM (2004) BRAF - Cohen Y et al. Clin Cancer Res (2004), Xing M et al. JCEM (2004), Salvatore G et al. JCEM (2004) Mutation panel/prospective study: BRAF, RET/PTC, RAS, PAX8/PPARg - Nikiforov et al., JCEM (2009) BRAF Mutations in Thyroid FNA Samples Samples (n) BRAF Positive Final Diagnosis in BRAF Positive Samples Thyroid Nodule FNA 9 Prospective Studies Thyroid Nodule FNA 7 Retrospective Studies 1, PTC = 159 (100%) PTC = 291 (100%) Research FNA of Surgically Removed Thyroid, 2 studies PTC = 130 (99.2%) HN*= 1 (0.8%) Total, 18 studies 2, PTC=580 (99.8%) HN*= 1 (0.2%) *Hyperplastic nodule reported as atypical nodular hyperplasia PTC - Papillary Thyroid Carcinoma Nikiforova MN & Nikiforov YE, Thyroid 2009 [Epub ahead of print]
11 Testing for Multiple Mutations in Thyroid FNA Samples Prospective study, , two centers (Univ. of Cincinnati, Univ. of Colorado) Thyroid nodule tested: 470 Mutation detected: 32 Risk of Cancer BRAF (18) 100% RAS (8) 87% RET/PTC (5) 100% PAX8/PPARg (1) 100% Nikiforov et al. JCEM (2009) Mutation Detection in Thyroid FNA Samples Results of Cytology and Molecular Analysis Cancer Probability in Thyroid Nodules Positive Cytology and Positive for Mutation 100% Indeterminate Cytology Alone 40.4% Indeterminate Cytology and Positive for Mutation 100% Indeterminate Cytology and Negative for Mutation 16.2% Negative cytology Alone 2.1% Negative cytology and Negative for Mutation 0.9% Nikiforov et al. JCEM (2009)
12 Molecular Testing of Thyroid FNA Samples with Indeterminate Cytology Cytology Diagnosis Molecular Testing (MT) HistologicDiagnosis MT Performance FLUS (21) 5-10% risk of malignancy Mutation Positive (3) BRAF (1), RAS(2) Mutation Negative(18) Malignant (3) PC (3) Benign (18) HN (15), FA (3) Sensitivity 100% Specificity 100% PPV 100% NPV 100% Accuracy 100% Follicular or Hürthle cell neoplasm (23) 20-30% risk of malignancy Mutation Positive (9) BRAF (4), RAS(3), PAX8/PPARγ(1), RET/PTC (1) Mutation Negative(18) Malignant (9) PC (7), FC (2) Malignant (3) PC (1), FC (2) Benign (11) HN (10), FA (1) Sensitivity 75% Specificity 100% PPV 100% NPV 79% Accuracy 87% Suspicious for malignancy (7) 50-75% risk of malignancy Mutation Positive (3) BRAF (4), RET/PTC (1) Mutation Negative(4) Malignant (3) PC (3) Sensitivity 60% Specificity 100% Malignant (2) PC (2) Benign (2) HN (2) PPV 100% NPV 50% Accuracy 71% Nikiforov et al. JCEM (2009) Molecular Testing of Thyroid FNA Samples at Univ. of Pittsburgh Clinical algorithm initiated in April 2007: Cytology Positive Indeterminate Negative MolecularTesting Molecular Testing for Mutations BRAF, BRAF, NRAS, NRAS, HRAS, HRAS, KRAS, KRAS, RET/PTC, RET/PTC, PTC,PAX8/PPAR? PAX8/PPARγ BRAF, RAS, RET/PTC, PAX8/PPARg Total NA Isolation Total NAIsolation Real-time PCR Real-time PCR Real-time RT-PCR Real-time RT-PCR
13 Results April February 2009 Thyroid nodule tested: 925 Mutation detected: 105 (11%) BRAF - 52 NRAS -34 HRAS KRAS - 2 RET/PTC -4 PAX8/PPARg -3 Mutation-positive nodules with surgery: 95 Nikiforov, JCEM, 2011, in press BRAF Mutations Molecular Cytology Histology BRAF+ (52) Surgery (50) MALIG (39) INDET (10) 4 FLUS 1 - FN 5 SUSP PTC (39) PTC (10) INSUF (1) PTC (1)
14 Case: 42 yo woman with right thyroid nodule Cytology Molecular Histology V600E WT FINAL DIAGNOSIS: FNA RIGHT THYROID: SATISFACTORY FOR INTERPRETATION. SUSPICIOUS FOR MALIGNANT CELLS. CLUSTERS OF ATYPICAL FOLLICULAR CELLS PRESENT SUSPICIOUS FOR PAPILALRY CARCINOMA. Addendum Molecular Anatomic Pathology Testing: THYROID, RIGHT, FINE NEEDLE ASPIRATION- A. BRAF T1799A mutation IS IDENTIFIED. B. Mutations in HRAS61, in NRAS61, HRAS61, and RET/PTC1, RET/PTC3 and PAX8/PPARg rearrangements NOT IDENTIFIED. FINAL DIAGNOSIS: THYROID, TOTAL THYROIDECTOMY (17.8 GRAMS) - A. PAPILLARY THYROID CARCINOMA, CONVENTIONAL TYPE, 1.1 CM B. NO EXTRATHYROIDAL EXTENSION. C. RESECTION MARGINS ARE NEGATIVE RAS Mutations Molecular Cytology Histology RAS+ (46) Surgery (39) INDET (39) FLUS (15) Foll. Neoplasm (18) SUSP (6) PTC (30) FTC (2) ATC (1) FA (4) HN (2) 85% 10% 5%
15 Case 2: 37 yo woman with right thyroid nodule Cytology Molecular Histology MUT WT FINAL DIAGNOSIS: FNA RIGHT THYROID: LESION OF UNDETERMINED SIGNIFICANCE. MACROPHAGES AND FEW FOLLICULAR GROUPS (SEE COMMENT). Addendum Molecular Anatomic Pathology Testing: THYROID, RIGHT, FINE NEEDLE ASPIRATION- A. NRAS61 mutation IS IDENTIFIED. B. Mutations in BRAF, HRAS61, KRAS12/13, and RET/PTC1, RET/PTC3 and PAX8/PPARg rearrangements NOT IDENTIFIED. FINAL DIAGNOSIS: THYROID, TOTAL THYROIDECTOMY (36 GRAMS) - A. PAPILLARY THYROID CARCINOMA, FOLLICULAR VARIANT, PARTIALLY ENCAPSULATED, 4.0 CM. B. NO ANGIOLYMPHATIC INVASION OR EXTRATHYROIDAL EXTENSION. C. RESECTION MARGINS ARE NEGATIVE. Molecular Testing of FNA Samples Diagnostic Impact Thyroid nodule tested: 925 Mutation detected (11%) Surgery performed - 95 Malignant - 89 (94%) Neoplastic - 93 (98%) Cancer diagnosis confirmed (cytology malignant) 43 patients Cancer diagnosis established (cytology indeterminate) 52 patients 20 - FLUS cytology 21 - FL cytology
16 BRAF and Aggressiveness of Papillary MicroCA Table 1 Analysis of BRAF V600E mutation in PTMCs BRAF mutation Positive (n = 24) Negative (n = 40) p Age (yr) 49.1 ± ± Male:female ratio 2:22 6: Nodular goiter 6 (25%) 8 (20%) Hashimoto thyroiditis 0 8 (20%) >0.99 Extrathyroidal extension 12 (50%) 4 (10%) 0.001* Nodes metastasis 12 (50%) 6 (15%) 0.003* Tall cell variant 2 (8.3%) 2 (5%) T 1 :T 3/4 ratio 12:12 36: * * Statistically significant Lee X et al. Ann Surg Oncol (2009) BRAF and Aggressiveness of Papillary Micro-carcinoma AGGRESSIVE GROUP N= 29 (26 PTS) NON-AGGRESSIVE GROUP N= 30 (28 PTS) P VALUE BRAF 20/26 (77%) 8/25 (32%) ANATOMIC LOCATION - LEFT LOBE/ RIGHT LOBE 15 (52%) / 14 (48%) 14 (47%) / 14 (47%) TUMOR LOCATION - SUBCAPSULAR 27 (93%) 9(30%) < POSITIVE MARGIN 2 (7%) 1 (3%) COMPLETE CAPSULE 2 (7%) 8 (27%) INFILTRATIVE BORDER 29 (100%) 24 (80%) MICROSCOPIC VARIANT - CLASSIC PAPILLARY 13 (45%) 11 (37%) FOLLICULAR VARIANT 8 (28.0%) 18 (60%) TALL CELL FEAT/VAR 8 (28%) 1 (3%) INTRATHYROIDAL SPREAD 22 (76%) 6 (20%) < FIBROSIS - NO 2 (7%) 9 (30%) YES, 1+ 3 (10%) 9 (30%) YES, (83%) 12 (40%) EXTRATHYROIDAL EXTENSION 19 (66%) 4 (13%) < MULTI-CENTRIC 6 (21%) 3 (10%) Niemeier L et al. Cancer, 2011, in press
17 Molecular-Pathological Score Defines Papillary MicroCA Aggressiveness Scoring Criteria BRAF Mutation + 2 Subcapsular (superficial) location 1 Extrathyroidal extension 1 Tumor fibrosis, 2+ 1 Intrathyoidal spread % MP Score, BRAF + 4 features aggressive control Score High risk Interm risk Low risk Niemeier L et al. Cancer, 2011, in press Revised Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer American Thyroid Association 2009
18 SUMMARY Molecular Analysis of Thyroid Neoplasms Known gene mutations occur in 75% of well differentiated thyroid carcinomas - can be detected in thyroid cytology and surgical samples In FNA samples, BRAF, RET/PTC, and PAX8/PPARg have a 100% PPV for cancer In FNA samples, RAS mutations have 85-87% PPV for cancer BRAF can be used as a molecular marker of aggressiveness in papillary carcinomas
Molecular Diagnostics in Thyroid Tumors
USCAP 2011 Endocrine Pathology Society Companion Meeting Molecular Diagnostics in Thyroid Tumors Yuri E. Nikiforov, M.D., Ph.D. Department of Pathology University of Pittsburgh Medical Center Outline Overview
More informationMarkers in Thyroid Nodule Evaluation. Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center
Markers in Thyroid Nodule Evaluation Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center Disclosures Quest Diagnostics (consultant) UPMC/CBLPath
More informationDilemmas in Cytopathology and Histopathology
Dilemmas in Cytopathology and Histopathology Yuri E. Nikiforov, MD, PhD Division of Molecular & Genomic Pathology University of Pittsburgh Medical Center, USA Objectives Discuss new WHO classification
More informationDr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital. NSW Health Pathology University of Sydney
Dr Catherine Woolnough, Hospital Scientist, Chemical Pathology, Royal Prince Alfred Hospital NSW Health Pathology University of Sydney Thyroid Cancer TC incidence rates in NSW Several subtypes - Papillary
More informationAmerican Society of Cytopathology Companion Society Symposium Uses and Misuses of Ancillary Tests in Cytopathology
American Society of Cytopathology Companion Society Symposium Uses and Misuses of Ancillary Tests in Cytopathology Zubair W. Baloch. MD, PhD. Professor of Pathology, UPENN Medical Center Perelman School
More informationUltrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events
Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules: New events Sandrine Rorive, M.D., PhD. Erasme Hospital - Université Libre de Bruxelles (ULB) INTRODUCTION The assessment of thyroid nodules
More information2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines
2015 American Thyroid Association Thyroid Nodule and Cancer Guidelines Angela M. Leung, MD, MSc, ECNU November 5, 2016 Outline Workup of nontoxic thyroid nodule(s) Ultrasound FNAB Management of FNAB results
More informationLet s Make Sense of Present & Predict Future. In Light of Past 1/12/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationThyroid Nodule Management
Thyroid Nodule Management Shane O. LeBeau, MD Clinical Associate Professor of Medicine Clinical Lead, Endocrine Thyroid Unit Division of Endocrinology, Diabetes and Metabolism University of Pittsburgh
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Molecular Markers in Fine Needle Aspirates of the Thyroid Policy Number: 2.04.78 Last Review: 3/2014 Origination: 3/2013 Next Review: 3/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationACCME/Disclosures. Questions to Myself? 4/11/2016
The New Diagnostic Paradigms in Thyroid Surgical Pathology and Affects on Reporting of Thyroid Fine-Needle Aspiration Specimens Deliberations, Criticisms & Discussions Zubair W. Baloch, MD, PhD. Professor
More informationSezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli Studi di Ferrara
Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli Studi di Ferrara Endocrinology Overview of genetic markers Molecular markers
More informationHow to Use Molecular Genetic Studies in Endocrine Disease? (in the Management of Well- Differentiated Thyroid Cancer) No Conflicts to Declare
How to Use Molecular Genetic Studies in Endocrine Disease? (in the Management of Well- Differentiated Thyroid Cancer) No Conflicts to Declare Quan-Yang Duh Professor of Surgery University of California,
More informationAPPROCCIO DIAGNOSTICO-TERAPEUTICO TERAPEUTICO AL CARCINOMA DIFFERENZIATO DELLA TIROIDE Sabato 6 aprile 2013 Aula Magna Nuovo Arcispedale S.
dal 1846 APPROCCIO DIAGNOSTICO-TERAPEUTICO TERAPEUTICO AL CARCINOMA DIFFERENZIATO DELLA TIROIDE Sabato 6 aprile 2013 Aula Magna Nuovo Arcispedale S. Anna Ruolo dell analisi genetica Maria Chiara Zatelli
More informationASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate. Thyroid Nodules: How Far Have We Come?
ASC Companion Meeting at the 2017 USCAP: Ancillary Molecular Testing in "Indeterminate Thyroid Nodules: How Far Have We Come? William C. Faquin, MD, PhD, Massachusetts General Hospital, Boston, MA The
More informationFollicular Derived Thyroid Tumors
Follicular Derived Thyroid Tumors Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for Medical Sciences
More informationThyroid Pathology: It starts and ends with the gross. Causes of Thyrophobia. Agenda. Diagnostic ambiguity. Treatment/prognosis disconnect
Thyroid Pathology: It starts and ends with the gross Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University of Arkansas for
More informationMedical Policy Manual. Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid. Date of Origin: April 2013
Medical Policy Manual Topic: Molecular Markers in Fine Needle Aspirates of the Thyroid Date of Origin: April 2013 Section: Genetic Testing Last Reviewed Date: April 2014 Policy No: 49 Effective Date: July
More informationSection 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014
Policy Number 2.04.82 Molecular Markers in Fine Needle Aspirates of the Thyroid Medical Policy Section 2 Original Policy Date 2013 Last Review Status/Date September 1, 2014 Disclaimer Our medical policies
More informationMaria Chiara Zatelli Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università
Maria Chiara Zatelli Sezione di Endocrinologia e Medicina Interna Direttore: Prof. Ettore degli Uberti Dipartimento di Scienze Mediche Università degli Studi di Ferrara Molecular markers? Endocrinology
More informationMolecular Testing for Indeterminate Thyroid Nodules. October 20, 2018
Molecular Testing for Indeterminate Thyroid Nodules October 20, 2018 Patient 1: Left 1.0 cm AP x 1.6 cm transverse x 2.1 cm in length Well defined Isoechoic heterogeneous No calcification Grade 3 Vascularity
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Markers in Fine Needle Aspirates of the Thyroid Page 1 of 25 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Markers in Fine Needle Aspirates
More information40 TH EUROPEAN CONGRESS 0F CYTOLOGY LIVERPOOL, UK October 2-5, 2016
Outcomes from the diagnostic approach of thyroid lesions using US-FNA and LBC in clinical practice Emmanouel Mastorakis MD PhD Cytopathologist Director in Cytopathology Laboratory Regional General Hospital
More informationTHYROID CYTOLOGY THYROID CYTOLOGY FINE-NEEDLE-ASPIRATION ANCILLARY TESTS IN THYROID FNA
ANCILLARY TESTS IN THYROID FNA Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Molecular Pathology Unit, IPATIMUP General-Secretary of the International
More informationCLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Molecular Markers for Fine Needle Aspirates of Thyroid Nodules MP-065-MD-DE Medical Management Provider Notice Date: 10/15/2018;
More informationAn Alphabet Soup of Thyroid Neoplasms
Overall Objectives An Alphabet Soup of Thyroid Neoplasms Lester D. R. Thompson www.lester-thompson.com What is the current management of papillary carcinoma? What are the trends and what can we do differently?
More informationAGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS
AGGRESSIVE VARIANTS OF PAPILLARY THYROID CARCINOMA DIAGNOSIS AND PROGNOSIS PAPILLARY THYROID CARCINOMA Clinical Any age Microscopic to large Female: Male= 2-4:1 Radiation history Lymph nodes Prognosis
More informationThyroid Cancer: When to Treat? MEGAN R. HAYMART, MD
Thyroid Cancer: When to Treat? MEGAN R. HAYMART, MD ASSOCIATE PROFESSOR OF MEDICINE UNIVERSITY OF MICHIGAN MICHIGAN AACE 2018 ANNUAL MEETING Thyroid Cancer: When Not to Treat? FOCUS WILL BE ON LOW-RISK
More informationThyroid Nodules. Family Medicine Refresher Course Geeta Lal MD, FACS April 2, No financial disclosures
Thyroid Nodules Family Medicine Refresher Course Geeta Lal MD, FACS April 2, 2014 No financial disclosures Objectives Review epidemiology Work up of Thyroid nodules Indications for FNAB Evolving role of
More informationDynamic Risk Stratification:
Dynamic Risk Stratification: Using Risk Estimates to Guide Initial Management R Michael Tuttle, MD Clinical Director, Endocrinology Service Memorial Sloan Kettering Cancer Center Professor of Medicine
More informationPEDIATRIC Ariel Katz MD
PEDIATRIC Ariel Katz MD Dept. Otolaryngology Head &Neck Surgery Wolfson Medical Center Holon, Israel OBJECTIVES Overview/Background Epidemiology/Etiology Intro to Guidelines Workup Treatment Follow-Up
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.78 Molecular Markers in Fine Needle Aspirates of the Thyroid Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November 26, 2014 Next
More information3/27/2017. Disclosure of Relevant Financial Relationships. Each year over 550,000 thyroid FNAs are performed in the U.S.!!! THYROID FNA: THE GOOD NEWS
Disclosure of Relevant Financial Relationships William C. Faquin, MD, PhD Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital Professor of Pathology Harvard Medical
More informationThe Bethesda Indeterminate Categories: An Update to Diagnosis and Molecular Testing
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director, Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital The Bethesda Indeterminate Categories:
More informationThyroid Cytopathology: Weighing In The Bethesda System
Thyroid Cytopathology: Weighing In The Bethesda System V8 Conflicts No financial consideration Bias Work in the Canadian environment where litigation is less Thyroid cytology is often referred in by small
More informationMolecular Markers in Fine Needle Aspirates of the Thyroid
Medical Policy Manual Genetic Testing, Policy No. 49 Molecular Markers in Fine Needle Aspirates of the Thyroid Next Review: April 2019 Last Review: June 2018 Effective: July 1, 2018 IMPORTANT REMINDER
More informationThyroid FNA: Diagnosis, Challenges and Solutions. Disclosures
Thyroid FNA: Diagnosis, Challenges and Solutions Zubair W. Baloch, MD, PhD None Disclosures 1 Questions to Myself? Where We are Now? The Present 2 Reality Check There is More to How Thyroid Nodules are
More informationCase #1 FNA of nodule in left lobe of thyroid in 67 y.o. woman
Challenging Cases Manon Auger M.D., F.R.C.P. (C) Professor, Department of Pathology McGill University Director, Cytopathology Laboratory McGill University it Health Center Case #1 FNA of nodule in left
More informationWork Up & Evaluation of Thyroid Nodules In 2013: State of The Art
Work Up & Evaluation of Thyroid Nodules In 2013: State of The Art BC Surgical Oncology Network, Fall Update Todd McMullen MD PhD FRCSC FACS Endocrine Surgeon Divisions of General Surgery and Oncology Director,
More informationPathology of the Thyroid
Pathology of the Thyroid Thyroid Carcinoma Arising from Follicular Cells 2015-01-19 Prof. Dr. med. Katharina Glatz Pathologie Carcinomas Arising from Follicular Cells Differentiated Carcinoma Papillary
More informationMedical Policy. Title: Genetic Testing- Molecular Markers in Fine Needle Aspirates (FNA) of the Thyroid
Medical Policy Joint Medical Policies are a source for BCBSM and BCN medical policy information only. These documents are not to be used to determine benefits or reimbursement. Please reference the appropriate
More informationCase #1. Ed Stelow, MD University of Virginia
Case #1 Ed Stelow, MD University of Virginia Imagine, If You Will It s 4:30 on Friday Last cytology case A thyroid FNA from outside that did not have any onsite interpretation It is from a 45-year old
More informationWTC 2013 Panel Discussion: Minimal disease
WTC 2013 Panel Discussion: Minimal disease Susan J. Mandel MD MPH Panelists Ken Ain Yasuhiro Ito Stephanie Lee Erich Sturgis Mark Urken Faculty/Presenter Disclosure Relationships with commercial interests
More informationManagement guideline for patients with differentiated thyroid cancer. Teeraporn Ratanaanekchai ENT, KKU 17 October 2007
Management guideline for patients with differentiated thyroid Teeraporn Ratanaanekchai ENT, KKU 17 October 2007 Incidence (Srinagarind Hospital, 2005, both sex) Site (all) cases % 1. Liver 1178 27 2. Lung
More informationRepeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results
Anatomic Pathology / REPEAT THYROID FINE-NEEDLE ASPIRATION Repeat Thyroid Nodule Fine-Needle Aspiration in Patients With Initial Benign Cytologic Results Melina B. Flanagan, MD, MSPH, 1 N. Paul Ohori,
More informationVolume 2 Issue ISSN
Volume 2 Issue 3 2012 ISSN 2250-0359 Correlation of fine needle aspiration and final histopathology in thyroid disease: a series of 702 patients managed in an endocrine surgical unit *Chandrasekaran Maharajan
More informationBuilding On The Best A Review and Update on Bethesda Thyroid 2017
Building On The Best A Review and Update on Bethesda Thyroid 2017 Syed Z. Ali, MD, FRCPath, FIAC Professor of Pathology and Radiology The Johns Hopkins Hospital, Baltimore, Maryland USA TBSRTC Diagnostic
More informationPersistent & Recurrent Differentiated Thyroid Cancer
Persistent & Recurrent Differentiated Thyroid Cancer Electron Kebebew University of California, San Francisco Department of Surgery Objectives Risk factors for persistent & recurrent disease Causes of
More informationThyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS
Thyroid Nodules: Understanding FNA Cytology (The Bethesda System for Reporting of Thyroid Cytopathology) Shamlal Mangray, MB, BS Attending Pathologist Rhode Island Hospital, Providence, RI DISCLOSURE:
More informationMolecular markers in thyroid cancers
Review Article DOI: 10.18203/issn.2456-3994.IntJMolImmunoOncol20172639 Molecular markers in thyroid cancers Alpa Nimesh Patel, Siddharth Singh Department of Internal Medicine, Pramukhswami Medical College,
More informationPre-operative Ultrasound of Lymph Nodes in Thyroid Cancer
Pre-operative Ultrasound of Lymph Nodes in Thyroid Cancer AACE - Advances in Medical and Surgical Management of Thyroid Cancer - 2018 Robert A. Levine, MD, FACE, ECNU Thyroid Center of New Hampshire Geisel
More informationTHE FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA AND NIFTP
THE FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA AND NIFTP FOLLICULAR VARIANT OF PAPILLARY CARCINOMA HISTORICAL PERSPECTIVE FOLLICULAR VARIANT OF PAPILLARY CARCINOMA 1960 described by Dr. Stuart Lindsay
More informationUltrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer
Ultrasound for Pre-operative Evaluation of Well Differentiated Thyroid Cancer Its Not Just About the Nodes AACE Advances in Medical and Surgical Management of Thyroid Cancer - 2017 Robert A. Levine, MD,
More informationHow to Handle Thyroid FNA
How to Handle Thyroid FNA Maoxin Wu, MD, PhD Chief of Cytopathology Director of Fine Needle Aspiration (FNA) and Core Biopsy Services Clinical Professor, Department of Pathology Joint appointment, Department
More informationNEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS. BY: Shifaa Qa qa
NEOPLASMS OF THE THYROID PATHOLOGY OF PARATHYROID GLANDS BY: Shifaa Qa qa Neoplasmas of the thyroid thyroid nodules Neoplastic ---- benign, malignant Non neoplastic Solitary nodules ----- neoplastic Nodules
More informationCase year old female presented with asymmetric enlargement of the left lobe of the thyroid
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationCase 4 Diagnosis 2/21/2011 TGB
Case 4 22 year old female presented with asymmetric enlargement of the left lobe of the thyroid gland. No information available relative to a prior fine needle aspiration biopsy. A left lobectomy was performed.
More informationDifferentiated Thyroid Carcinoma
Differentiated Thyroid Carcinoma The GOOD cancer? Jennifer Sipos, MD Associate Professor of Medicine Director, Benign Thyroid Program Division of Endocrinology, Diabetes and Metabolism The Ohio State University
More informationThyroid Nodules. No conflicts. Overview 5/16/2017. UCSF Internal Medicine Updates May 22, 2017 Elizabeth Murphy, MD, DPhil
Thyroid Nodules UCSF Internal Medicine Updates May 22, 2017 Elizabeth Murphy, MD, DPhil No conflicts Overview Thyroid nodule and cancer review Ultrasound FNA cytology Nodule follow up Putting it all together
More informationCN 925/15 History. Microscopic Findings
CN 925/15 History 78 year old female. FNA indeterminate lesion right thyroid lobe. Previous THY1C (UK) Bethesda category 1 cyst fluid. Ultrasound showed part solid/cystic changes, indeterminate in nature
More informationBackground to the Thyroid Nodule
William C. Faquin, MD, PhD Professor of Pathology Harvard Medical School Director of Head and Neck Pathology Massachusetts Eye and Ear Massachusetts General Hospital THYROID FNA: PART I Background to the
More informationThyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.
Thyroid Gland Protocol applies to all malignant tumors of the thyroid gland, except lymphomas. Procedures Cytology (No Accompanying Checklist) Partial Thyroidectomy Total Thyroidectomy With/Without Lymph
More information4/22/2010. Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey.
Management of Differentiated Thyroid Cancer: Head Neck Surgeon Perspective Hakan Korkmaz, MD Assoc. Prof. of Otolaryngology Ankara Dıșkapı Training Hospital-Turkey Thyroid gland Small endocrine gland:
More informationWhat s an NIFTP? Keeping Up To Date in Thyroid 2018
What s an NIFTP? Keeping Up To Date in Thyroid 2018 Kathleen Hands, MD, FACE, ECNU Director, Thyroid Center of South Texas Assistant Clinical Professor UTHSCSA DrHands@Thyroid-Center.com 210-844-6163 text
More informationNormal thyroid tissue
Thyroid Pathology Overview Normal thyroid tissue Normal thyroid tissue with follicles filled with colloid. Thyroid cells form follicles, spheres of epithelial cells (always single layered in health, usually
More informationOverview of Indeterminate Cytology
83 rd Annual Meeting American Thyroid Association Overview of Indeterminate Cytology Scott Boerner MD FRCPC Head Cytopathology, University Health Network University of Toronto DISCLOSURE Nothing to disclose
More informationAACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration
AACE Thyroid Cancer Tumor board 25 years of the Endocrine and Surgery collaboration Dr. Peter Singer, Endocrinology Dr. Peter Sadow, Pathology Moderator Dr. Greg Randolph, Otolaryngology Relevant Financial
More information3/22/2017. Disclosure of Relevant Financial Relationships. Cytomorphologic Thresholds for Classifying Thyroid FNAs as Suspicious and Positive for PTC
Cytomorphologic Thresholds for Classifying Thyroid FNAs as Suspicious and Positive for PTC Tarik M. Elsheikh, MD Professor and Medical Director Anatomic Pathology Cleveland Clinic Laboratories Disclosure
More information04/09/2018. Follicular Thyroid Tumors Updates in Classification & Practical Tips. Dissecting Indeterminants. In pursuit of the low grade malignancy
Follicular Thyroid Tumors Updates in Classification & Practical Tips Jennifer L. Hunt, MD, MEd Aubrey J. Hough Jr, MD, Endowed Professor of Pathology Chair of Pathology and Laboratory Medicine University
More informationOh, I get it, the TSH goes up and down
Evaluation and Management of the Thyroid Nodule Oh, I get it, the TSH goes up and down UCSF Head and Neck Conference October 24, 2008 Peter A. Singer, M.D. Professor and Chief Clinical Endocrinology University
More informationNew entities in thyroid pathology: update according to the WHO classification
New entities in thyroid pathology: update according to the WHO classification R.R. de Krijger, Dept. of Pathology, University Medical Center and Princess Maxima Center, Utrecht, The Netherlands New issues
More informationThyroid nodules - medical and surgical management. Endocrinology and Endocrine Surgery Manchester Royal Infirmary
Thyroid nodules - medical and surgical management JRE Davis NR Parrott Endocrinology and Endocrine Surgery Manchester Royal Infirmary Thyroid nodules - prevalence Thyroid nodules common, increase with
More informationMolecular biopathology of thyroid tumors
Molecular biopathology of thyroid tumors Philippe Vielh MD, PhD, FIAC Director of Cytopathology Deputy Director of Anatomic Pathology National Health Laboratory of Luxembourg Past President of the International
More informationManagement of Thyroid Nodules. February 2 nd, 2018 Sarah Hopkins
Management of Thyroid Nodules February 2 nd, 2018 Sarah Hopkins No disclosures Goals: Review Initial Evaluation of Thyroid Nodules Review Indications for Biopsy Approach to Multinodular Goiter Review Management
More informationCytomorphologic Thresholds for Classifying Thyroid FNAs as Suspicious and Positive for PTC
Cytomorphologic Thresholds for Classifying Thyroid FNAs as Suspicious and Positive for PTC Tarik M. Elsheikh, MD Professor and Medical Director Anatomic Pathology Cleveland Clinic Laboratories Case Study
More informationEvaluation and Management of Thyroid Nodules. Overview of Thyroid Nodules and Their Management. Thyroid Nodule detection: U/S versus Exam
Overview of Thyroid Nodules and Their Management Matthew D. Ringel, M.D. Professor of Medicine Divisions of Endocrinology and Oncology, The Ohio State University Co-Director, Thyroid Cancer Unit Arthur
More informationGerard M. Doherty, MD
Surgical Management of Differentiated Thyroid Cancer: Update on 2015 ATA Guidelines Gerard M. Doherty, MD Chair of Surgery Utley Professor of Surgery and Medicine Boston University Surgeon-in-Chief Boston
More informationMolecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine-needle Aspiration Biopsy
World J Surg (2010) 34:2589 2594 DOI 10.1007/s00268-010-0720-0 Molecular Testing for Somatic Mutations Improves the Accuracy of Thyroid Fine-needle Aspiration Biopsy Willieford Moses Julie Weng Ileana
More informationPRACTICE GUIDELINES: Thyroid Nodules and Cancer 2017 ESEO Alexandria
PRACTICE GUIDELINES: Thyroid Nodules and Cancer 2017 ESEO Alexandria James V. Hennessey MD Associate Professor of Medicine Harvard Medical School Case 1 28 year old woman sees OB for routine visit ROS:
More information"Atypical": Criteria and
"Atypical": Criteria and Controversies Esther Rossi MD PhD MIAC Division of Anatomic Pathology and Cytology Catholic University of Sacred Heart Rome, Italy CASE HISTORY In 2015, 45 y/o woman underwent
More informationHow Will (Should) the Latest Guidelines Affect the Endocrinologist s Management of Thyroid Cancer? AACE 2017
How Will (Should) the Latest Guidelines Affect the Endocrinologist s Management of Thyroid Cancer? AACE 2017 Bryan R. Haugen, MD University of Colorado, School of Medicine Outline Some statistics New guidelines
More informationTBSRTC 1- Probabilistic approach and Relationship to Clinical Algorithms
The Benefits of a Uniform Reporting System for Thyroid Cytopathology BETHESDA REPORTING SYSTEM Prof. Fernando Schmitt Department of Pathology and Oncology, Medical Faculty of Porto University Head of Molecular
More informationDIAGNOSIS AND REPORTING OF FOLLICULAR-PATTERNED THYROID LESIONS BY FINE NEEDLE ASPIRATION
Follicular-patterned thyroid lesions, WC Faquin 1 DIAGNOSIS AND REPORTING OF FOLLICULAR-PATTERNED THYROID LESIONS BY FINE NEEDLE ASPIRATION William C. Faquin, M.D., Ph.D Department of Pathology, Massachusetts
More information5/3/2017. Ahn et al N Engl J Med 2014; 371
Alan Failor, M.D. Clinical Professor of Medicine Division of Metabolism, Endocrinology and Nutrition University of Washington April 20, 2017 No disclosures to report 1. Appropriately evaluate s in adult
More informationResearch Article Impact of Molecular Testing in the Diagnosis of Thyroid Fine Needle Aspiration Cytology: Data from Mainland China
Disease Markers, Article ID 912182, 6 pages http://dx.doi.org/10.1155/2014/912182 Research Article Impact of Molecular Testing in the Diagnosis of Thyroid Fine Needle Aspiration Cytology: Data from Mainland
More informationNIFTP Cytologic Aspects
NIFTP Cytologic Aspects William C. Faquin, MD PhD Director, Head and Neck Pathology Massachusetts General Hospital & Massachusetts Eye and Ear Infirmary Boston, MA USA So, what is the story about FVPTC
More informationNIFTP: Histopathology of a Cytological Monkey Wrench. B. Wehrli
NIFTP: Histopathology of a Cytological Monkey Wrench B. Wehrli Non-Invasive Encapsulated Follicular Variant of Papillary Thyroid Carcinoma Before 2016 Non-Invasive Follicular Thyroid Neoplasm with Papillary-Like
More informationUpdate on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center
Update on Thyroid FNA The Bethesda System Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center Thyroid Nodules Frequent occurrence Palpable: 4-7% of adults Ultrasound: 10-31% Majority benign
More informationCase Report Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms
Hindawi Publishing Corporation Volume 2015, Article ID 153932, 5 pages http://dx.doi.org/10.1155/2015/153932 Case Report Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms Shiuan-Li
More informationTitle: Detection of BRAF Mutations on Direct Smears of Thyroid Fine Needle Aspirates through
Title: Detection of BRAF Mutations on Direct Smears of Thyroid Fine Needle Aspirates through Cell Transfer Technique Concise Title: BRAF on cell transfer cytology Qiuying Shi, MD; Ashley Ibrahim, MD; Kristi
More information3/29/2012. Thyroid cancer- what s new. Thyroid Cancer. Thyroid cancer is now the most rapidly increasing cancer in women
Thyroid cancer- what s new Thyroid Cancer Changing epidemiology Molecular markers Lymph node dissection Technical advances rhtsh Genetic testing and prophylactic surgery Vandetanib What s new? Jessica
More informationBRAF V600E Does Not Predict Aggressive Features of Pediatric Papillary Thyroid Carcinoma
The Laryngoscope VC 2014 The American Laryngological, Rhinological and Otological Society, Inc. BRAF V600E Does Not Predict Aggressive Features of Pediatric Papillary Thyroid Carcinoma Daniel J. Givens,
More informationCase Report Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms
Case Reports in Pathology Volume 2015, Article ID 153932, 5 pages http://dx.doi.org/10.1155/2015/153932 Case Report Tumor-to-Tumor Metastasis: Lung Carcinoma Metastasizing to Thyroid Neoplasms Shiuan-Li
More informationCAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release
CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release 2 REVISION HISTORY Date Author / Editor Comments 5/19/2014 Jaleh Mirza Created the document 8/12/2014 Samantha Spencer/Jaleh
More informationNCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology
The Bethesda System For Reporting Thyroid Cytopathology Towards a Uniform Terminology With Management Guidelines NCI Thyroid FNA State of the Science Conference Bethesda, MD October 22-23, 2007 154 registrants
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Markers in Fine Needle Aspirates of the Thyroid Page 1 of 40 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Markers in Fine Needle Aspirates
More informationThe Bethesda System for Reporting Thyroid Cytopathology, Laila Khazai 11/4/17
The Bethesda System for Reporting Thyroid Cytopathology, 2017 Laila Khazai 11/4/17 In Summary No major changes for cytologists. The clinical team is faced with different risk of malignancies (ROM) associated
More informationKey Topics in Thyroid Cancer Worldwide epidemic What Should the Endocrinologist and Surgeon do?
Key Topics in Thyroid Cancer Worldwide epidemic What Should the Endocrinologist and Surgeon do? Martin Schlumberger Gustave Presenter Roussy Name and Université Paris Saclay, Villejuif, France 1 Disclosure
More informationA Study of Thyroid Swellings and Correlation between FNAC and Histopathology Results
International Journal of Current Microbiology and Applied Sciences ISSN: 2319-7706 Volume 6 Number 4 (2017) pp. 265-269 Journal homepage: http://www.ijcmas.com Original Research Article https://doi.org/10.20546/ijcmas.2017.604.030
More information